Hormone replacement therapy (HRT) is one of the most debated topics in women's health — generating strong opinions in both directions. For many Indian women, HRT is dismissed without proper consideration because of cancer fears rooted in a 2002 study (the Women's Health Initiative — WHI) whose findings have since been significantly reinterpreted and contextualised.

The current evidence-based position is that HRT is the most effective treatment for menopausal symptoms, is appropriate for most healthy women under 60, and in many women offers long-term health benefits beyond symptom relief.

Dr. Shachi Singh, consultant gynaecologist at Prakash Hospital, Sector 33, Noida, explains the modern evidence.

---

What HRT Is

HRT replaces the oestrogen (and in women with a uterus, progesterone) that the body stops producing at menopause. The goal is to restore hormone levels sufficient to relieve menopausal symptoms and provide organ-protective effects.

Types of HRT:

Combined HRT (oestrogen + progestogen): For women with a uterus. Oestrogen alone stimulates the endometrial lining — adding progestogen protects against endometrial hyperplasia and cancer. Can be given as:

• Continuous combined (oestrogen and progestogen daily) — no periods
• Sequential/cyclical (oestrogen daily, progestogen added for 12 to 14 days per cycle) — produces a withdrawal bleed, suitable in perimenopause

Oestrogen-only HRT: For women who have had a hysterectomy (no uterus = no endometrial cancer risk from oestrogen alone).

Routes of administration:

• Oral tablets — convenient, well-studied
• Transdermal patches — avoids first-pass liver metabolism, lower clot risk than oral
• Transdermal gel — applied daily to skin
• Implants — subcutaneous pellets, less common

The route matters clinically: Transdermal oestrogen (patches, gel) does not increase clotting risk — unlike oral oestrogen, which passes through the liver and raises clotting factors. For women with any increased VTE (thrombosis) risk, transdermal is preferred.

---

The WHI Study and the Rethink

The 2002 Women's Health Initiative (WHI) study found that combined oral HRT (conjugated equine oestrogen plus medroxyprogesterone acetate — a synthetic progestin) increased breast cancer risk, blood clots, and stroke in women with an average age of 63. This caused a global abandonment of HRT that persisted for over a decade.

The reinterpretation that has emerged from decades of subsequent analysis:

• The WHI cohort was older (average 63 — significantly older than typical HRT users, who start around menopause at 50 to 51)
• The synthetic progestin used (MPA) is associated with higher breast cancer risk than natural progesterone (micronised progesterone) — the formulations used in the WHI are not what is recommended today
• Starting HRT in women already more than 10 years past menopause carries different risk profiles than starting in newly menopausal women ("the timing hypothesis" or "window of opportunity")
• Transdermal oestrogen eliminates the VTE risk shown for oral oestrogen

---

Current Consensus: Who Benefits and Who Should Be Cautious

Women who benefit most and have the best safety profile:

• Women under 60 or within 10 years of menopause onset
• Women with moderate to severe menopausal symptoms significantly affecting quality of life
• Women with premature menopause (before 50) — HRT is specifically recommended for health protection in these women, not just symptom relief, until the age of natural menopause
• Women with high fracture risk or osteoporosis — HRT significantly protects bone density

Non-symptom benefits of HRT when started early:

• Bone density protection (reduces fracture risk)
• Cardiovascular protection when started within 10 years of menopause (the "timing hypothesis")
• Reduced colorectal cancer risk
• Possible cognitive protection

Women where HRT requires specialist assessment:

• Personal history of breast cancer — HRT is generally contraindicated, though specific formulations and clinical situations are assessed individually
• Hormone-receptor-positive cancers
• Personal history of VTE (blood clots) — transdermal HRT may be appropriate
• Uncontrolled hypertension, severe liver disease
• BRCA carriers — require specialist genetic oncology and gynaecology input

---

HRT and Breast Cancer: The Actual Numbers

The breast cancer risk associated with HRT has been significantly recontextualised. Current estimates for combined HRT (oestrogen + modern progestogen):

• After 5 years of combined HRT: approximately 4 to 6 extra cases per 1,000 women over 5 years
• This risk is comparable to drinking one to two alcoholic drinks daily or having an elevated BMI

For perspective: being overweight carries a higher breast cancer risk than standard combined HRT. The risk largely disappears within 2 to 5 years of stopping HRT.

Oestrogen-only HRT does not increase breast cancer risk — and may slightly reduce it.

---

Gynaecological Care in Noida and Greater Noida

Dr. Shachi Singh at Prakash Hospital, Sector 33, Noida, provides personalised menopause and HRT consultation for women across Noida and Greater Noida — helping women make informed decisions about hormonal and non-hormonal treatment options.

To book a consultation with Dr. Shachi Singh, call: +91 97023 46853

Clinic Hours: Monday to Saturday, 9 AM – 6 PM | Sunday, 10 AM – 2 PM

Clinic Address: D-12A, 12B, Sector-33, G.B. Nagar, Noida, Uttar Pradesh 201301

---

This blog is for educational purposes only. HRT decisions must be made individually with a qualified gynaecologist based on personal risk factors and symptom burden.